.After antibody-drug conjugate (ADC) expert Seagen was sold to Pfizer last year for a massive $43 bi...
.On the heels of a phase 3 gain that stopped working to blow away real estate investors, Ironwood Ph...
.Don't quit Monte Rosa Rehabs now. The Boston-based biotech is actually having a ball after authoriz...
.Accept to this week's Chutes & Ladders, our roundup of substantial leadership hirings, shootings...
.Celebrating his business's upsized going public (IPO), Septerna CEO Jeffrey Finer called the openin...
.AbbVie has returned to the resource of its own antipsychotic powerhouse Vraylar seeking another run...
.GenSight Biologics is actually full weeks out of running out of money. Once more. The biotech only ...
.Monopar Rehabs is recovering a medication coming from the scrap heap of AstraZeneca's rare ailment ...
.Along with brand-new records out on Arcus Biosciences' experimental HIF-2a inhibitor, one team of e...
.After developing a genetics treatment collaboration along with Dyno Rehabs in 2020, Roche is back f...